ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II clinical trial of its innovative bispecific antibody, IMM0306, aimed at treating Lupus Nephritis. This development marks a significant step for the company as it continues to advance its cutting-edge therapies targeting CD47 and CD20 to improve therapeutic outcomes. Investors and shareholders are advised to stay informed as the company progresses with this promising treatment.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departing Philadelphia Sports Arena
- It’s Official: Ford (NYSE:F) Is Number Seven
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
